IL97306A - 4-) Di-N-profile (amino-6-aminocarbonyl-1,3,4,5-tetrahydrobenzo] CD [indole Hiport crystalline process for its preparation Pharmacological preparations containing or - Google Patents

4-) Di-N-profile (amino-6-aminocarbonyl-1,3,4,5-tetrahydrobenzo] CD [indole Hiport crystalline process for its preparation Pharmacological preparations containing or

Info

Publication number
IL97306A
IL97306A IL9730691A IL9730691A IL97306A IL 97306 A IL97306 A IL 97306A IL 9730691 A IL9730691 A IL 9730691A IL 9730691 A IL9730691 A IL 9730691A IL 97306 A IL97306 A IL 97306A
Authority
IL
Israel
Prior art keywords
hippurate
amino
propyl
tetrahydrobenz
indole
Prior art date
Application number
IL9730691A
Other languages
English (en)
Hebrew (he)
Other versions
IL97306A0 (en
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL97306A0 publication Critical patent/IL97306A0/xx
Publication of IL97306A publication Critical patent/IL97306A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/90—Benzo [c, d] indoles; Hydrogenated benzo [c, d] indoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL9730691A 1990-02-26 1991-02-20 4-) Di-N-profile (amino-6-aminocarbonyl-1,3,4,5-tetrahydrobenzo] CD [indole Hiport crystalline process for its preparation Pharmacological preparations containing or IL97306A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48518590A 1990-02-26 1990-02-26

Publications (2)

Publication Number Publication Date
IL97306A0 IL97306A0 (en) 1992-05-25
IL97306A true IL97306A (en) 1996-10-16

Family

ID=23927224

Family Applications (1)

Application Number Title Priority Date Filing Date
IL9730691A IL97306A (en) 1990-02-26 1991-02-20 4-) Di-N-profile (amino-6-aminocarbonyl-1,3,4,5-tetrahydrobenzo] CD [indole Hiport crystalline process for its preparation Pharmacological preparations containing or

Country Status (28)

Country Link
US (1) US5397799A (no)
EP (1) EP0444852B1 (no)
JP (1) JP3157007B2 (no)
KR (1) KR100208114B1 (no)
CN (1) CN1027503C (no)
AT (1) ATE126506T1 (no)
AU (1) AU629453B2 (no)
BR (1) BR9100767A (no)
CA (1) CA2037099C (no)
CY (1) CY1887A (no)
DE (1) DE69112099T2 (no)
DK (1) DK0444852T3 (no)
ES (1) ES2077796T3 (no)
FI (1) FI95464C (no)
GR (1) GR3017940T3 (no)
HK (1) HK175495A (no)
HU (1) HU217118B (no)
IE (1) IE67801B1 (no)
IL (1) IL97306A (no)
LV (1) LV10251B (no)
NO (1) NO174149C (no)
NZ (1) NZ237181A (no)
PT (1) PT96852B (no)
RU (2) RU2034837C1 (no)
SG (1) SG69975A1 (no)
TW (1) TW219933B (no)
YU (1) YU47594B (no)
ZA (1) ZA911258B (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5302612A (en) * 1990-02-26 1994-04-12 Eli Lilly And Company 6-substituted-hexahydrobenz[cd]indoles
IL97308A (en) * 1990-02-26 1996-10-31 Lilly Co Eli Xahydrobenz [DC] Induced indoles in position 6, their preparation process and pharmaceutical preparations containing them
IL97309A (en) * 1990-02-26 1996-11-14 Lilly Co Eli Intermediates for hexahydrobenz] [DC indoles and a process for making their pure enantiomers
US5364856A (en) * 1991-03-28 1994-11-15 Eli Lilly And Company 6-heterocyclic-4-amino-1,3,4,5-tetrahydrobenz[CD]indoles
US5643934A (en) * 1991-03-28 1997-07-01 Eli Lilly And Company 6-heterocyclic-4-amino-1,2,2a,3,4,5-hexahydrobenz [CD]indoles
TW248556B (no) * 1993-01-18 1995-06-01 Takeda Pharm Industry Co
US7588924B2 (en) 2006-03-07 2009-09-15 Procter & Gamble Company Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
EP3026044B8 (en) * 2006-06-26 2018-12-19 Akebia Therapeutics, Inc. Prolyl hydroxylase inhibitors and methods of use
CN102595896B (zh) 2009-11-06 2016-02-17 爱尔皮奥治疗有限公司 提高低氧诱导因子-1α的稳定性的方法
NO2686520T3 (no) 2011-06-06 2018-03-17
WO2012170439A1 (en) 2011-06-06 2012-12-13 The Ohio State University Methods for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer
CN114404414A (zh) 2013-06-13 2022-04-29 阿克比治疗有限公司 用于治疗贫血症的组合物和方法
AR099354A1 (es) 2013-11-15 2016-07-20 Akebia Therapeutics Inc Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, composiciones, y sus usos
WO2016118858A1 (en) 2015-01-23 2016-07-28 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
BR112017021097B1 (pt) 2015-04-01 2024-01-02 Akebia Therapeutics, Inc Formulação de dosagem oral e seu uso
TWI822776B (zh) 2018-05-09 2023-11-21 美商阿克比治療有限公司 用於製備2-[[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基]乙酸之方法
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4110339A (en) * 1977-11-25 1978-08-29 Eli Lilly And Company 4-(Di-n-propyl)amino-1,3,4,5-tetrahydrobenz[cd]indole
US4576959A (en) * 1984-02-06 1986-03-18 Eli Lilly And Company 6-Substituted-4-dialkylaminotetrahydrobenz[c,d]indoles
US4745126A (en) * 1987-03-12 1988-05-17 Eli Lilly And Company Method of treating anxiety with tetrahydrobenz[c,d]indole-6-carboxamides
DE3809155A1 (de) * 1988-03-18 1989-09-28 Bayer Ag 1,3,4,5-tetrahydrobenz-(c,d)-indole
US5204340A (en) * 1989-04-11 1993-04-20 Eli Lilly And Company Tetrahydrobenz(c,d)indole serotonin agonists
US5229409A (en) * 1990-08-15 1993-07-20 Eli Lilly And Company 6-substituted-tetrahydrobenz[cd]indoles

Also Published As

Publication number Publication date
GR3017940T3 (en) 1996-02-29
LV10251B (en) 1995-04-20
CA2037099C (en) 2001-09-11
HK175495A (en) 1995-11-24
HU217118B (hu) 1999-11-29
CN1054589A (zh) 1991-09-18
EP0444852A2 (en) 1991-09-04
LV10251A (lv) 1994-10-20
YU47594B (sh) 1995-10-24
IL97306A0 (en) 1992-05-25
US5397799A (en) 1995-03-14
FI910895A (fi) 1991-08-27
ES2077796T3 (es) 1995-12-01
JPH04217662A (ja) 1992-08-07
PT96852A (pt) 1991-10-31
BR9100767A (pt) 1991-10-29
DE69112099D1 (de) 1995-09-21
SG69975A1 (en) 2000-01-25
HUT56542A (en) 1991-09-30
CN1027503C (zh) 1995-01-25
JP3157007B2 (ja) 2001-04-16
NO910735L (no) 1991-08-27
YU32791A (sh) 1994-01-20
FI95464C (fi) 1996-02-12
DE69112099T2 (de) 1996-02-08
RU2083561C1 (ru) 1997-07-10
KR910021375A (ko) 1991-12-20
ZA911258B (en) 1992-10-28
NO910735D0 (no) 1991-02-25
TW219933B (no) 1994-02-01
NZ237181A (en) 1992-06-25
AU7197191A (en) 1991-08-29
PT96852B (pt) 1998-07-31
AU629453B2 (en) 1992-10-01
NO174149B (no) 1993-12-13
FI910895A0 (fi) 1991-02-25
IE910625A1 (en) 1991-08-28
ATE126506T1 (de) 1995-09-15
RU2034837C1 (ru) 1995-05-10
FI95464B (fi) 1995-10-31
NO174149C (no) 1994-03-23
CY1887A (en) 1996-04-05
DK0444852T3 (da) 1995-12-11
EP0444852A3 (en) 1992-02-19
EP0444852B1 (en) 1995-08-16
CA2037099A1 (en) 1991-08-27
KR100208114B1 (ko) 1999-07-15
IE67801B1 (en) 1996-05-01

Similar Documents

Publication Publication Date Title
EP0444852B1 (en) Crystalline salt of 4-(di-n-propyl)amino-6-aminocarbonyl-1,3,4,5-tetrahydrobenz[cd]indole
CA2493310C (en) 3-z-[1-(4-(n-((4-methyl-piperazin-1-yl)-methylcarbonyl)-n-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate and the use thereof as a pharmaceutical composition
CA2029265C (en) 4- and 6-carbamates related to physostigmine, a process and intermediates for their preparation and their use as medicaments
KR101468827B1 (ko) 카베딜롤 인산염 및(또는) 그의 용매화물, 상응하는 조성물, 및(또는) 치료 방법
CA2110574A1 (en) Tryptamine analogues, their synthesis and their use as 5-ht1-like or 5-ht2 receptor agonists
NO171453B (no) Fremgangsmaate for fremstilling av krystallinsk paroxetin-hydroklorid-hemihydrat
JPS59112964A (ja) インドロン化合物
US6706710B2 (en) Form of (R)-N-[5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamide
US20040242619A1 (en) Processes for preparation of polymorphic forms of desloratadine
JP3898219B2 (ja) フエニルインドール化合物
KR20030042038A (ko) 온단세트론 히드로클로라이드의 신규한 결정 형태 및용매화물 형태와 이들의 제조 방법
MXPA04010845A (es) Formas cristalinas novedosas de ondansetron, procesos para su preparacion, composiciones farmaceuticas que contienen las formas novedosas y metodos para tratar las nauseas utilizando las mismas.
CA2084442A1 (en) Indole derivatives
EA011894B1 (ru) Новая псевдополиморфная форма деслоратадина, образованная с диоксидом углерода
FI102173B (fi) Menetelmä terapeuttisesti käyttökelpoisten heksahydrobents£CD|indolien valmistamiseksi
JP2009504595A (ja) ペリンドプリルエルブミンの調製方法
MXPA04010846A (es) Proceso para preparar 1, 2, 3, 9-tetrahidro -9- metil-3 -[(2-metil -1h-imidazol -1-il) metil]- 4h- carbazol -4- ona.
CA2372236A1 (en) Polymorphs of crystalline (2-benzhydryl-1-azabicyclo¬2,2,2|oct-3-yl)-(5-isopropyl-2-methoxybenzyl)-amine citrate as nk-1 receptor antagonists
JPH07188218A (ja) 大脳機能活性剤ｂｍｙ−２１５０２ヘミ水和物
IE913663A1 (en) Ergoline derivatives
NZ245707A (en) Substituted indole derivatives
KR20050019792A (ko) 카베딜롤 인산염 및(또는) 그의 용매화물, 상응하는조성물, 및(또는) 치료 방법

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees